Literature DB >> 20399219

Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models.

Ji-Kyung Choi1, Isabel Carreras, Alpaslan Dedeoglu, Bruce G Jenkins.   

Abstract

There is evidence that inositol isomers may help protect against formation of toxic fibrils of Abeta fragments in Alzheimer's disease mouse models. Scyllo-inositol is one of the more promising inositol isomers for the potential treatment of Alzheimer's disease (AD) and can be detected using MRS in human subjects. In this manuscript we demonstrate using MRS, in two different mouse models of AD (APP x PS1 and APP x PS1 x tau), that we could detect increased scyllo-inositol in the hippocampus and frontal cortex in mice fed water supplemented with 16.5 mg/L of scyllo-inositol equivalent to about 3.3 mg/kg/day. We used both brain extracts using solution MRS as well as intact brain tissue using high resolution magic angle spinning (HRMAS) to ensure that any membrane-associated scyllo-inositol would be detected. By brain extracts we detected a 3.0 fold increase in scyllo-inositol in the scyllo-fed AD mice compared to normal diet (p < 0.001). Using HRMAS we detected a 2.2-2.4-fold increase in scyllo-inositol (p < 0.001). Scyllo-inositol treatment was associated with an increase in glutamine in hippocampus. The concentrations of scyllo-inositol were higher in the hippocampus than in the frontal cortex. Mice have a smaller concentration of scyllo-inositol than humans (ca. 100 microM vs. 500 microM in humans). Given the ease with which scyllo-inositol can be measured in human MRS data with high signal to noise ratios, these data suggest that MRS will prove useful for evaluation of inositol treatment trials in AD subjects. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399219      PMCID: PMC2926267          DOI: 10.1016/j.neuropharm.2010.03.011

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  24 in total

1.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

2.  Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

Authors:  Hai-Wei Wang; Joseph F Pasternak; Helen Kuo; Helen Ristic; Mary P Lambert; Brett Chromy; Kirsten L Viola; William L Klein; W Blaine Stine; Grant A Krafft; Barbara L Trommer
Journal:  Brain Res       Date:  2002-01-11       Impact factor: 3.252

3.  Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice.

Authors:  B G Jenkins; P Klivenyi; E Kustermann; O A Andreassen; R J Ferrante; B R Rosen; M F Beal
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  myo-inositol: a newly identified nonnitrogenous osmoregulatory molecule in mammalian brain.

Authors:  J H Thurston; W R Sherman; R E Hauhart; R F Kloepper
Journal:  Pediatr Res       Date:  1989-11       Impact factor: 3.756

5.  The transport and metabolism of scyllo-inositol in the central nervous system.

Authors:  R Spector
Journal:  J Neurochem       Date:  1978-10       Impact factor: 5.372

6.  Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.

Authors:  J McLaurin; R Golomb; A Jurewicz; J P Antel; P E Fraser
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

7.  Multinuclear NMR studies on the energy metabolism of glial and neuronal cells.

Authors:  A Brand; C Richter-Landsberg; D Leibfritz
Journal:  Dev Neurosci       Date:  1993       Impact factor: 2.984

8.  Probable Alzheimer disease: diagnosis with proton MR spectroscopy.

Authors:  T K Shonk; R A Moats; P Gifford; T Michaelis; J C Mandigo; J Izumi; B D Ross
Journal:  Radiology       Date:  1995-04       Impact factor: 11.105

9.  Identification of Scyllo-inositol in proton NMR spectra of human brain in vivo.

Authors:  T Michaelis; G Helms; K D Merboldt; W Hänicke; H Bruhn; J Frahm
Journal:  NMR Biomed       Date:  1993 Jan-Feb       Impact factor: 4.044

10.  Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile.

Authors:  Alpaslan Dedeoglu; Ji-Kyung Choi; Kerry Cormier; Neil W Kowall; Bruce G Jenkins
Journal:  Brain Res       Date:  2004-06-25       Impact factor: 3.252

View more
  12 in total

1.  Combination therapy in a transgenic model of Alzheimer's disease.

Authors:  Bruce G Jenkins; Alpaslan Dedeoglu; Nurgul Aytan; Ji-Kyung Choi; Isabel Carreras; Neil W Kowall
Journal:  Exp Neurol       Date:  2013-10-10       Impact factor: 5.330

2.  Protective effects of 7,8-dihydroxyflavone on neuropathological and neurochemical changes in a mouse model of Alzheimer's disease.

Authors:  Nurgul Aytan; Ji-Kyung Choi; Isabel Carreras; Leah Crabtree; Brian Nguyen; Margaret Lehar; Jan Krzysztof Blusztajn; Bruce G Jenkins; Alpaslan Dedeoglu
Journal:  Eur J Pharmacol       Date:  2018-03-03       Impact factor: 4.432

Review 3.  A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra.

Authors:  Caroline D Rae
Journal:  Neurochem Res       Date:  2013-11-21       Impact factor: 3.996

Review 4.  Applications of high-resolution magic angle spinning MRS in biomedical studies I-cell line and animal models.

Authors:  Eva Kaebisch; Taylor L Fuss; Lindsey A Vandergrift; Karin Toews; Piet Habbel; Leo L Cheng
Journal:  NMR Biomed       Date:  2017-03-16       Impact factor: 4.044

5.  1H-MRS assessment of the therapeutic effect of bilateral intraventricular BDNF infusion into APP/PS1 double transgenic mice.

Authors:  Wei Zhang; Pei-jun Wang; Ming-hua Li; Guo-liang Wang; Ping Li; Xiao-long Gao
Journal:  J Mol Neurosci       Date:  2013-01-15       Impact factor: 3.444

6.  The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging.

Authors:  Ji-Kyung Choi; Isabel Carreras; Nur Aytan; Eric Jenkins-Sahlin; Alpaslan Dedeoglu; Bruce G Jenkins
Journal:  Brain Res       Date:  2014-10-06       Impact factor: 3.252

7.  Sodium/myo-Inositol transporters: substrate transport requirements and regional brain expression in the TgCRND8 mouse model of amyloid pathology.

Authors:  Daniela Fenili; Ying-Qi Weng; Isabelle Aubert; Mark Nitz; JoAnne McLaurin
Journal:  PLoS One       Date:  2011-08-26       Impact factor: 3.240

8.  Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease.

Authors:  Nurgul Aytan; Ji-Kyung Choi; Isabel Carreras; Volker Brinkmann; Neil W Kowall; Bruce G Jenkins; Alpaslan Dedeoglu
Journal:  Sci Rep       Date:  2016-04-27       Impact factor: 4.379

9.  Diastereoselective synthesis of new O-alkylated and C-branched inositols and their corresponding fluoro analogues.

Authors:  Charlotte Collet; Françoise Chrétien; Yves Chapleur; Sandrine Lamandé-Langle
Journal:  Beilstein J Org Chem       Date:  2016-02-25       Impact factor: 2.883

10.  A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes.

Authors:  Dohyun Lee; Woo-Sirl Lee; Sungsu Lim; Yun Kyung Kim; Hoe-Yune Jung; Sanket Das; Juhyun Lee; Wenjie Luo; Kyong-Tai Kim; Sung-Kee Chung
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.